Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Tumor cell invasion and metastasis are critical factors in poor cancer patient prognosis.
• Targeted drug delivery systems are crucial for improving cancer treatment efficacy.
• CD44 and N-cadherin are key markers associated with tumor cell migration and invasion.

Purpose of the Study:

• To construct a dual-targeting drug delivery system based on mesoporous silica nanoparticles (MSNs) for inhibiting tumor cell invasion and metastasis.
• To evaluate the efficacy of the CD44 and N-cadherin dual-targeting system in vitro.
• To investigate the mechanism of action for inhibiting tumor cell metastasis.

Main Methods:

• Synthesis of amino-modified MSNs (MSN/NH2) and functionalization with hyaluronic acid (HA) and ADH-1 to create ADH-1-HA-MSN.
• Loading of doxorubicin hydrochloride (DOX) as a model anticancer drug.
• Characterization of the nanocarrier, evaluation of cellular uptake via flow cytometry and confocal microscopy, cytotoxicity assays, Transwell chamber assays for migration and invasion, and Western blotting for N-cadherin expression analysis.

Main Results:

• The ADH-1-HA-MSN nanocarrier exhibited a spherical shape with a narrow particle size distribution.
• Hyaluronic acid modification significantly enhanced CD44-mediated cellular uptake.
• ADH-1-HA-MSN/DOX demonstrated higher cytotoxicity and markedly inhibited tumor cell migration and invasion compared to controls.
• Western blotting confirmed that ADH-1-HA-MSN/DOX inhibited tumor cell invasion and metastasis by down-regulating N-cadherin expression.

Conclusions:

• The developed ADH-1-HA-MSN nanocarrier effectively targets CD44 and N-cadherin.
• This dual-targeting system shows significant potential for inhibiting cancer cell invasion and metastasis.
• ADH-1-HA-MSN represents a promising targeted drug delivery platform for cancer therapy.